keyword
MENU ▼
Read by QxMD icon Read
search

Dotatate

keyword
https://www.readbyqxmd.com/read/30325820/18f-fdg-68ga-dotatate-and-68ga-psma-positive-metastatic-large-cell-neuroendocrine-prostate-tumor
#1
Emine Acar, Gamze Çapa Kaya
Prostate large cell neuroendocrine tumor is a rare disease. In this case, metastatic areas showing FDG uptake, somatostatin receptor positivity, and PSMA expression are shown in F-FDG PET/CT, Ga-DOTATATE PET/CT, and Ga-PSMA PET/CT in a 70-year-old man with the diagnosis of prostate large cell neuroendocrine carcinoma.
October 15, 2018: Clinical Nuclear Medicine
https://www.readbyqxmd.com/read/30308585/resistant-functioning-and-or-progressive-symptomatic-metastatic-gastroenteropancreatic-neuroendocrine-tumors-efficacy-of-177lu-dotatate-peptide-receptor-radionuclide-therapy-in-this-setting
#2
Ashwini Kalshetty, Anant Ramaswamy, Vikas Ostwal, Sandip Basu
BACKGROUND AND AIMS: Functioning and symptomatic disease resistant to conventional therapies constitutes a subset amongst neuroendocrine tumors (NETs) that are commonly considered for peptide receptor radionuclide therapy (PRRT). The aim of this study was to evaluate the efficacy of Lu-DOTATATE PRRT in this group with objective assessment criteria. MATERIALS AND METHODS: A total of 46 patients with refractory or progressive symptomatic GEP-NETs (previously treated at various stages with long-acting octreotide, chemotherapy, multikinase inhibitors, etc...
October 10, 2018: Nuclear Medicine Communications
https://www.readbyqxmd.com/read/30295930/gastroenteropancreatic-neuroendocrine-tumors
#3
REVIEW
Mauro Cives, Jonathan R Strosberg
Neuroendocrine tumors (NETs) are heterogeneous malignancies arising from the diffuse neuroendocrine system. They frequently originate in the gastroenteropancreatic (GEP) tract and the bronchopulmonary tree, and their incidence has steadily increased in the last 3 decades. Fundamental biologic and genomic differences underlie the clinical heterogeneity of NETs, and distinct molecular features characterize NETs of different grades and different primary sites. Although surgery remains the cornerstone of treatment for localized tumors, systemic treatment options for patients with metastatic NETs have expanded considerably...
October 8, 2018: CA: a Cancer Journal for Clinicians
https://www.readbyqxmd.com/read/30291986/chelation-formulation-encapsulation-retention-and-in-vivo-biodistribution-of-hydrophobic-nanoparticles-labelled-with-57-co-porphyrin-oleylamine-ensures-stable-chelation-of-cobalt-in-nanoparticles-that-accumulate-in-tumors
#4
Pablo Hervella, Johan HygumDam, Helge Thisgaard, Christina Baun, Birgitte Brinkmann Olsen, Poul Flemming Høilund-Carlsen, David Needham
BACKGROUND AND MOTIVATION: While small molecules can be used in cancer diagnosis there is a need for imageable diagnostic NanoParticles (NPs) that act as surrogates for the therapeutic NPs. Many NPs are composed of hydrophobic materials so the challenge is to formulate hydrophobic imaging agents. To develop individualized medical treatments based on NP, a first step should be the selection of patients who are likely responders to the treatment as judged by imaging tumor accumulation of NPs...
October 3, 2018: Journal of Controlled Release: Official Journal of the Controlled Release Society
https://www.readbyqxmd.com/read/30283629/diagnosing-microscopic-pancreatic-neuroendocrine-tumor-using-68-ga-dotatate-pet-ct-case-series
#5
Martin Barrio, Eugene P Ceppa
Neuroendocrine tumors (NETs) are an uncommon diagnosis which often present asymptomatically or with vague symptoms. They can originate from many different organs such as the GI tract, lungs, pancreas and others. 68 Gallium DOTATATE positron emission topography/computed topography has been shown to be an effective imaging modality for diagnosing NET and evaluating management options for patients. Here, we present two cases of positive findings in the distal pancreas on the DOTATATE PET/CT scans without any morphological lesion found to be NET in a healthy 48-year-old male and 68-year-old male...
September 2018: Journal of Surgical Case Reports
https://www.readbyqxmd.com/read/30273206/increased-activity-due-to-fractures-does-not-significantly-affect-the-accuracy-of-68ga-dotatate-pet-ct-in-the-detection-of-culprit-tumor-in-the-evaluation-of-tumor-induced-osteomalacia
#6
Jie Ding, Guilan Hu, Ling Wang, Fang Li, Li Huo
OBJECTIVE: Ga-DOTATATE PET/CT is currently the most common imaging modality in localizing culprit tumors, which can result in tumor-induced osteomalacia (TIO). Fracture, which is one of the most common consequences of the TIO, can also lead to increased Ga-DOTATATE activity and potentially affect the accuracy of Ga-DOTATATE PET/CT imaging. The aim of this investigation is to evaluate whether the increased Ga-DOTATATE activity at the sites of the fracture will cause interpretation difficulty in the localizing the culprit tumor causing TIO...
September 28, 2018: Clinical Nuclear Medicine
https://www.readbyqxmd.com/read/30267071/radioguided-surgery-with-gallium-68-dotatate-for-patients-with-neuroendocrine-tumors
#7
Mustapha El Lakis, Andreas Gianakou, Pavel Nockel, Douglas Wiseman, Amit Tirosh, Martha A Quezado, Dhaval Patel, Naris Nilubol, Karel Pacak, Samira M Sadowski, Electron Kebebew
Importance: Neuroendocrine tumors (NETs) express somatostatin receptors, which can be targeted with radiolabeled peptides. In a variety of solid tumors, radioguided surgery (RGS) has been used to guide surgical resection. Gallium 68 (68Ga) dota peptides have been shown to be more accurate than other radioisotopes for detecting NETs. A pilot study previously demonstrated the feasibility and safety of 68Ga-dotatate RGS for patients with NETs. Objective: To evaluate what intraoperative techniques and thresholds define positive lesions that warrant resection during 68Ga-dotatate RGS...
September 26, 2018: JAMA Surgery
https://www.readbyqxmd.com/read/30254185/a-patient-derived-xenograft-model-of-pancreatic-neuroendocrine-tumors-identifies-sapanisertib-as-a-possible-new-treatment-for-everolimus-resistant-tumors
#8
Chester E Chamberlain, Michael S German, Katherine Yang, Jason Wang, Henry VanBrocklin, Melanie Regan, Kevan M Shokat, Gregory S Ducker, Grace E Kim, Byron Hann, David B Donner, Robert S Warren, Alan P Venook, Emily K Bergsland, Danny Lee, Yucheng Wang, Eric K Nakakura
Patients with pancreatic neuroendocrine tumors (PNETs) commonly develop advanced disease and require systemic therapy. However, treatment options remain limited, in part because experimental models that reliably emulate PNET disease are lacking. We therefore developed a patient-derived xenograft model of PNET (PDX-PNET) which we then used to evaluate two mTOR inhibitor drugs: FDA-approved everolimus and the investigational new drug sapanisertib. PDX-PNETs maintained a PNET morphology and PNET-specific gene expression signature with serial passage...
September 25, 2018: Molecular Cancer Therapeutics
https://www.readbyqxmd.com/read/30239510/targeted-therapy-new-radiolabeled-somatostatin-analogs-to-treat-gastroenteropancreatic-neuroendocrine-tumors
#9
Jean E Boucher, Robin Sommers
Neuroendocrine tumors (NETs), including gastroenteropancreatic NETs, or GEP-NETs, are heterogenous tumors that arise from diffuse neuroendocrine cells and other organs, such as the lung, ovary, and thyroid. Lutetium Lu 177 dotatate (Lutathera®) is a newly approved targeted therapy for patients with advanced GEP-NETs. Patients treated with octreotide long-acting release may be candidates for this second-line therapy. This article discusses lutetium Lu 177 dotatate therapy administration and patient care considerations...
October 1, 2018: Clinical Journal of Oncology Nursing
https://www.readbyqxmd.com/read/30237849/-177-lutetium-dotatate-delays-decline-in-quality-of-life-in-patients-with-midgut-neuroendocrine-tumors
#10
EDITORIAL
Jonathan Strosberg
No abstract text is available yet for this article.
September 4, 2018: Oncotarget
https://www.readbyqxmd.com/read/30236163/identification-and-characterization-of-myocardial-metastases-in-neuroendocrine-tumor-patients-using-68ga-dotatate-pet-ct
#11
Wolfgang G Kunz, Ralf S Eschbach, Robert Stahl, Philipp M Kazmierczak, Peter Bartenstein, Axel Rominger, Christoph J Auernhammer, Christine Spitzweg, Jens Ricke, Clemens C Cyran
BACKGROUND: Focal 68Ga-DOTATATE PET lesions within the myocardium of neuroendocrine tumor (NET) patients are observed in clinical practice. We determined the frequency and characteristics of lesions that are consistent with cardiac metastasis and assessed the lesion detection rate of conventional imaging. METHODS: 629 patients who underwent 68Ga-DOTATATE PET-CT at a supraregional comprehensive cancer center on NET were included from a consecutive registry. Inclusion criteria were: (1) focal 68Ga-DOTATATE tracer uptake within the myocardium in more than two sequential PET exams, and (2) contrast-enhanced CT...
September 20, 2018: Cancer Imaging: the Official Publication of the International Cancer Imaging Society
https://www.readbyqxmd.com/read/30235495/metastatic-phaeochromocytoma-spinning-towards-more-promising-treatment-options
#12
Svenja Nölting, Ashley Grossman, Karel Pacak
Phaeochromocytomas (PCC) and paragangliomas (PGL) are rare tumours arising from the chromaffin cells of the adrenal medulla (PCC) or the paraganglia located outside the adrenal gland (PGL). However, their incidence is likely to be underestimated; around 10% of all PCC/PGL are metastatic, with higher metastatic potential of PGLs compared to PCCs. If benign, surgery is the treatment of choice, but if metastatic, therapy is challenging. Here we review the currently existing therapy options for metastatic PCCs/PGLs including conventional chemotherapy (the original Averbuch scheme, but updated), radiopharmaceutical treatments (131 I-MIBG, 90 Y- and 177 Lu-DOTATATE) and novel targeted therapies (anti-angiogenic tyrosine kinase inhibitors and mTORC1 inhibitors), emphasising future therapeutic approaches (HIF-2α and PARP inhibitors, temozolomide alone, metronomic temozolomide, somatostatin analogues) based on the oncogenic signalling pathways related to three different clusters comprising more than 20 well-characterised PCC/PGL susceptibility genes...
September 20, 2018: Experimental and Clinical Endocrinology & Diabetes
https://www.readbyqxmd.com/read/30209002/everolimus-lutetium-177-dotatate-and-sunitinib-for-advanced-unresectable-or-metastatic-neuroendocrine-tumours-with-disease-progression-a-systematic-review-and-cost-effectiveness-analysis
#13
Ruben Mujica-Mota, Jo Varley-Campbell, Irina Tikhonova, Chris Cooper, Ed Griffin, Marcela Haasova, Jaime Peters, Stefano Lucherini, Juan Talens-Bou, Linda Long, David Sherriff, Mark Napier, John Ramage, Martin Hoyle
BACKGROUND: Neuroendocrine tumours (NETs) are a group of heterogeneous cancers that develop in cells in the diffuse neuroendocrine system. OBJECTIVES: To estimate the clinical effectiveness of three interventions [everolimus (Afinitor® ; Novartis International AG, Basel, Switzerland), lutetium-177 DOTATATE (177Lu-DOTATATE) (Lutathera® ; Imaging Equipment Ltd, Radstock, UK) and sunitinib (Sutent® ; Pfizer Inc., New York, NY, USA)] for treating unresectable or metastatic NETs with disease progression and establish the cost-effectiveness of these interventions...
September 2018: Health Technology Assessment: HTA
https://www.readbyqxmd.com/read/30199102/a-method-for-tumour-dosimetry-based-on-hybrid-planar-spect-ct-images-and-semi-automatic-segmentation
#14
Daniel Roth, Johan Gustafsson, Anna Sundlöv, Katarina Sjögreen Gleisner
PURPOSE: A hybrid planar-SPECT/CT method for tumour dosimetry in 177 Lu-DOTATATE therapy, applicable to data sets consisting of multiple conjugate-view images and one SPECT/CT, is developed and evaluated. METHODS: The imaging protocol includes conjugate-view imaging at 1 h, 24 h, 96 h, and 168 h post infusion (p.i.), and a SPECT/CT acquisition 24 h p.i. The dosimetry method uses the planar images to estimate the shape of the time-activity concentration curve, which is then rescaled to absolute units using the SPECT-derived activity concentration...
September 10, 2018: Medical Physics
https://www.readbyqxmd.com/read/30181398/first-report-of-concomitant-pheochromocytoma-and-duodenal-neuroendocrine-tumour-in-a-sporadic-multiple-endocrine-neoplasia-type-1
#15
Banafsheh Motazedi, Maziar Rahmani, James M Welch, Abbas Motazedi
A 77-year-old woman was diagnosed with pheochromocytoma followed by adrenalectomy at age 57. Hyperparathyroidism without osteoprosis was diagnosed at age 58. At age 75, Dual Energy X-ray Absoptiometry (DEXA) revealed osteoporosis and sestamibi scan showed a left parathyroid adenoma. Criteria for parathyroidectomy were met, and she underwent parathyroidectomy. Furthermore, she presented with haematochezia at age 75. An abdominal CT demonstrated a mass in the second portion of the duodenum. Additionally, octreoscan revealed somatostatin receptor positive tissue in the duodenum and Gallium 68 dotatate scan also showed a well-differentiated duodenal neuroendocrine tumour (NET)...
September 4, 2018: BMJ Case Reports
https://www.readbyqxmd.com/read/30179917/recurrence-of-extramedullary-plasmacytomas-involving-lymph-nodes-and-pancreas-revealed-by-68ga-dotatate-and-18f-fdg-pet-ct
#16
Qingqing Pan, Yaping Luo, Jian Li, Shu Zhang, Fang Li
A 40-year-old man with history of extramedullary plasmacytoma in nasal cavity presented with right submandibular mass for 3 months. F-FDG PET/CT demonstrated mild radioactivity in the right submandibular mass, pancreatic mass, and lymph nodes in the abdomen and left hilum of the lung. To differentiate from pancreatic neuroendocrine tumor, Ga-DOTATATE PET/CT was performed. The above lesions were TATE avid, and additional lesions with intense radioactivity were also detected in the right internal mammary node and intrapericardial node...
August 31, 2018: Clinical Nuclear Medicine
https://www.readbyqxmd.com/read/30170196/effects-of-adding-an-albumin-binder-chain-on-177-lu-lu-dotatate
#17
Etienne Rousseau, Joseph Lau, Zhengxing Zhang, Carlos F Uribe, Hsiou-Ting Kuo, Chengcheng Zhang, Jutta Zeisler, Nadine Colpo, Kuo-Shyan Lin, François Bénard
INTRODUCTION: [177 Lu]Lu-DOTATATE peptide receptor radionuclide therapy is used for treatment of neuroendocrine tumours. We investigated whether prolonging blood residence time of [177 Lu]Lu-DOTATATE with albumin binders could increase tumour accumulation and tumour-to-kidney ratios for improved therapeutic efficacy. METHODS: DOTATATE and its derivatives with an albumin-binder motif (GluAB-DOTATATE and AspAB-DOTATATE) were prepared by solid-phase peptide synthesis...
August 9, 2018: Nuclear Medicine and Biology
https://www.readbyqxmd.com/read/30151794/large-cardiac-metastasis-from-pancreatic-neuroendocrine-tumor-and-response-to-peptide-receptor-radionuclide-therapy-with-177-lu-dotatate
#18
Rahul V Parghane, Sandip Basu
No abstract text is available yet for this article.
August 27, 2018: Journal of Nuclear Cardiology: Official Publication of the American Society of Nuclear Cardiology
https://www.readbyqxmd.com/read/30139884/bilateral-orbital-soft-tissue-metastases-from-renal-neuroendocrine-tumor-successful-theranostic-application-of-68-ga-177-lu-dotatate-with-improvement-of-vision
#19
Rahul Vithalrao Parghane, Sandip Basu
Gratifying clinical response obtained in the clinical setting of bilateral orbital metastases from renal neuroendocrine tumor (NET) is reported. Methods: A 53 year-old male, diagnosed case of renal NET (MIB1 index-4%), with symptoms of skeletal and abdominal pain, proptosis and decrease in vision of left eye, was found to harbor bilateral orbital soft tissue lesions on 68 Ga-DOTATATE PET-CT and MRI in addition to widespread metastatic skeletal lesions, and metastatic lymph nodal disease. His symptoms worsened despite radiotherapy to left eye (20Gy) and long-acting octreotide therapy for 18 months, with increase in serum chromogranin A (CgA) level and was considered for 177 Lutetium(Lu)-DOTATATE peptide receptor radionuclide therapy (PRRT)...
August 23, 2018: Journal of Nuclear Medicine Technology
https://www.readbyqxmd.com/read/30115686/peptide-receptor-radionuclide-therapy-in-grade-3-neuroendocrine-neoplasms-safety-and-survival-analysis-in-69-patients
#20
Jingjing Zhang, Harshad R Kulkarni, Aviral Singh, Karin Niepsch, Dirk Müller, Richard P Baum
To date, limited data are available concerning peptide receptor radionuclide therapy (PRRT) of grade 3 (G3) neuroendocrine neoplasms (NENs) with a Ki-67 proliferation index of >20%. The purpose of this study was to analyze the long-term outcome, efficacy and safety of PRRT in patients with SSTR-expressing G3 NEN. Methods: A total of 69 patients (M=41 males; age 28-81 years) received PRRT with lutetium-177 (177 Lu) and/or yttium-90 (90 Y) labeled somatostatin analogs (DOTATATE or DOTATOC). Twenty-two patients had radiosensitising chemotherapy...
August 16, 2018: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
keyword
keyword
164118
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"